Is BIO a good stock to buy right now?

Based on our 6-factor quantitative model, BIO-RAD LABORATORIES, INC. (BIO) receives a "Hold" rating with a composite score of 41.6/100. It is ranked #1,811 out of 4,446 stocks. Key factor scores: Quality 44/100, Value 47/100, Momentum 42/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BIO?

BIO-RAD LABORATORIES, INC. (BIO) has a "Hold" rating and 3-star score. The composite score of 41.6 ranks it #1,811 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BIO in?

BIO-RAD LABORATORIES, INC. operates in the Technology sector (Measuring And Control Equipment industry) with a market cap of $7.51 billion. It is classified as a mid-cap stock.

Does BIO pay a dividend?

BIO does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is BIO's P/E ratio?

BIO has a trailing P/E ratio of 10.83x. The Technology sector average is 45.3x. This below-average P/E may indicate the stock is undervalued.

How profitable is BIO?

BIO's quality factor score is 44/100. Gross margin: 53.2%. ROE: 9.3% vs sector average -1.4%. High margins suggest pricing power and competitive moats.

How is BIO valued compared to peers?

BIO's value factor score is 47/100 (higher = cheaper). Key multiples: P/E 10.8x, EV/EBITDA 46.1x. Valuation is roughly in line with peers.

What is BIO's debt level?

BIO's debt-to-equity ratio is 16%. Sector average: 43%. Low leverage suggests conservative financial management.

BIO has a beta of 0.98, meaning it tracks the market. Stability score: 63/100.

Does BIO have high short interest?

BIO's short interest factor score is 17/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

BIO Stock Analysis: Top Mid-Cap Hold (Score 41.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
BIO	+0.63%	-0.26%	+4.26%	-7.84%	+20.22%	-	-	-
Industry Proxy XLK	+0.39%	+4.88%	+2.05%	-0.94%	-26.62%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.70%	-3.87%	+3.92%	-7.47%	-9.31%	-	-	-
Alpha vs Sector	+0.24%	-5.14%	+2.21%	-6.90%	+46.84%	-	-	-

Metric	BIO	Benchmark
P/E Ratio	10.8x	-76%
EV/EBITDA	46.1x	+261%
Price / Book	1.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
VRSN VERISIGN INC/CA	56	79	59	40	30.7x	-41.1%	88.0%	50.6%	8.3%	-87.0x	$23.0B	VS
IHS IHS Holding Ltd	55	42	63	63	-	-616.0%	48.0%	-96.1%	-	365.0x	$2.8B	VS
LHX L3HARRIS TECHNOLOGIES, INC. /DE/	55	50	52	66	37.5x	9.0%	25.5%	8.1%	10.3%	110.0x	$66.1B	VS
ESP ESPEY MFG & ELECTRONICS CORP	53	48	44	71	25.8x	12.8%	29.0%	17.1%	-11.7%	66.0x	$169M	VS
NYAX Nayax Ltd.	52	38	46	78	-	-13.6%	44.6%	-1.8%	-	30.0x	$2.2B	VS
ESE ESCO TECHNOLOGIES INC	52	49	40	69	65.6x	7.4%	40.8%	10.4%	16.3%	9.0x	$7.6B	VS
INTT INTEST CORP	52	50	32	72	-	-3.2%	43.1%	-3.1%	-22.8%	46.0x	$179M	VS
KARO Karooooo Ltd.	49	50	72	53	-	117.1%	69.5%	20.3%	-	10.0x	$1.6B	VS
MTC MMTec, Inc.	47	32	40	96	-	-1,370.8%	81.6%	-4,879.7%	-	120.0x	$136M	VS
CCLD CareCloud, Inc.	47	38	71	60	12.4x	18.5%	48.0%	9.6%	10.6%	47.0x	$154M	VS
BIO BIO-RAD LABORATORIES, INC.	42	44	47	42	10.8x	9.3%	53.2%	27.0%	2.3%	16.0x	$7.5B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.5%	0.5%	0.5%	0.5%	0.6%	0.6%	0.6%	0.5%	0.5%	0.5%	0.6%
Operating Margin %	0.1%	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%	0.1%	-0.0%	0.1%	0.0%
EBITDA Margin %	-0.1%	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%	0.1%	0.2%	0.1%	0.0%
Net Margin %	0.3%	0.3%	-0.7%	-0.2%	-1.3%	1.5%	1.5%	0.8%	0.2%	0.1%	0.0%
FCF Margin %	-14.1%	-	11.3%	-	-	-	18.7%	-4.3%	6.8%	-0.3%	-7.7%
ROE %	0.1%	0.1%	-0.3%	-0.1%	-0.4%	0.3%	0.4%	0.3%	0.1%	0.0%	0.0%
ROA %	0.1%	0.1%	-0.2%	-0.1%	-0.3%	0.2%	0.3%	0.2%	0.1%	0.0%	0.0%
ROIC %	0.0%	0.4%	2.9%	2.7%	4.0%	2.8%	3.6%	3.3%	-2.0%	3.1%	1.7%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.5%

0.6%

0.5%

0.6%

Operating Margin %

0.1%

0.0%

0.1%

0.2%

0.1%

-0.0%

0.1%

0.0%

EBITDA Margin %

-0.1%

0.0%

0.1%

0.2%

0.1%

0.2%

0.1%

0.0%

Net Margin %

0.3%

-0.7%

-0.2%

-1.3%

1.5%

0.8%

0.2%

0.1%

0.0%

FCF Margin %

-14.1%

11.3%

18.7%

-4.3%

6.8%

-0.3%

-7.7%

ROE %

0.1%

-0.3%

-0.1%

-0.4%

0.3%

0.4%

0.3%

0.1%

0.0%

ROA %

0.1%

-0.2%

-0.1%

-0.3%

0.2%

0.3%

0.2%

0.1%

0.0%

ROIC %

0.0%

0.4%

2.9%

2.7%

4.0%

2.8%

3.6%

3.3%

-2.0%

3.1%

1.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$2.5B	$2.6B	$2.6B	$2.7B	$2.8B	$2.9B	$2.5B	$2.3B	$2.3B	$2.2B	$2.1B	$2.0B
	—	$1.2B	—	$1.2B	$1.2B	$1.3B	—	—	—	—	—	—
	$1.4B	$1.3B	$1.4B	$1.4B	$1.6B	$1.6B	$1.4B	$1.3B	$1.2B	$1.2B	$1.1B	$1.1B
Gross Margin	53.2%	51.9%	53.7%	53.4%	55.9%	56.1%	56.5%	54.4%	53.4%	55.0%	55.0%	55.5%
	—	$844M	—	$842M	$828M	$880M	—	—	—	—	—	—
Research & Development	—	$276M	$296M	$247M	$257M	$272M	$218M	$203M	$199M	$250M	$206M	$193M
Depreciation	—	—	$0	—	—	—	$0	$0	$0	$0	$0	$0
Total Operating Expenses	—	$1.3B	—	$1.1B	$1.1B	$1.2B	—	—	—	—	—	—
	$231M	$47M	$269M	$338M	$483M	$489M	$421M	$230M	-$103M	$117M	$56M	$167M
EBIT	$231M	$47M	$269M	$338M	$483M	$489M	$421M	$230M	-$103M	$117M	$56M	$167M
EBITDA	-$254M	$47M	$363M	$338M	$483M	$489M	$444M	$254M	$537M	$121M	$65M	$168M
Operating Margin	8.9%	1.8%	10.5%	12.7%	17.2%	16.8%	16.6%	9.9%	-4.5%	5.5%	2.7%	8.3%
EBITDA Margin	-10.0%	1.8%	14.2%	12.6%	17.2%	16.7%	17.4%	11.0%	23.4%	5.6%	3.1%	8.3%
	—	$49M	$49M	$49M	$38M	$2M	$22M	$23M	$24M	$22M	$23M	$22M
	—	$996M	—	-$850M	-$4.7B	$5.4B	—	—	—	—	—	—
Income Tax Expense	—	$236M	-$498M	-$213M	-$1.1B	$1.2B	$1.1B	$502M	$147M	-$24M	$16M	$33M
	$693M	$760M	-$1.8B	-$637M	-$3.6B	$4.2B	$3.8B	$1.8B	$366M	$122M	$26M	$113M
Net Margin	27.0%	29.4%	-71.9%	-23.9%	-129.4%	145.3%	149.8%	76.1%	16.0%	5.7%	1.3%	5.4%
	$27.87	$27.87	$-65.36	$-21.82	$-121.79	$142.33	$128.13	$58.93	$12.25	$4.12	$0.88	$3.87
Diluted EPS	$27.87	$27.85	$-65.36	$-21.82	$-121.79	$140.56	$128.13	$58.93	$12.25	$4.12	$0.88	$3.87
Weighted Avg Basic	—	27M	—	29M	30M	30M	—	—	—	—	—	—
Weighted Avg Diluted	—	27M	—	29M	30M	30M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$2.5B

$2.6B

$2.7B

$2.8B

$2.9B

$2.5B

$2.3B

$2.2B

$2.1B

$2.0B

—

$1.2B

—

$1.2B

$1.3B

—

$1.4B

$1.3B

$1.4B

$1.6B

$1.4B

$1.3B

$1.2B

$1.1B

Gross Margin

53.2%

51.9%

53.7%

53.4%

55.9%

56.1%

56.5%

54.4%

53.4%

55.0%

55.5%

—

$844M

—

$842M

$828M

$880M

—

Research & Development

—

$276M

$296M

$247M

$257M

$272M

$218M

$203M

$199M

$250M

$206M

$193M

Depreciation

—

Total Operating Expenses

—

$1.3B

—

$1.1B

$1.2B

—

$231M

$47M

$269M

$338M

$483M

$489M

$421M

$230M

-$103M

$117M

$56M

$167M

EBIT

$231M

$47M

$269M

$338M

$483M

$489M

$421M

$230M

-$103M

$117M

$56M

$167M

EBITDA

-$254M

$47M

$363M

$338M

$483M

$489M

$444M

$254M

$537M

$121M

$65M

$168M

Operating Margin

8.9%

1.8%

10.5%

12.7%

17.2%

16.8%

16.6%

9.9%

-4.5%

5.5%

2.7%

8.3%

EBITDA Margin

-10.0%

1.8%

14.2%

12.6%

17.2%

16.7%

17.4%

11.0%

23.4%

5.6%

3.1%

8.3%

—

$49M

$38M

$2M

$22M

$23M

$24M

$22M

$23M

$22M

—

$996M

—

-$850M

-$4.7B

$5.4B

—

Income Tax Expense

—

$236M

-$498M

-$213M

-$1.1B

$1.2B

$1.1B

$502M

$147M

-$24M

$16M

$33M

$693M

$760M

-$1.8B

-$637M

-$3.6B

$4.2B

$3.8B

$1.8B

$366M

$122M

$26M

$113M

Net Margin

27.0%

29.4%

-71.9%

-23.9%

-129.4%

145.3%

149.8%

76.1%

16.0%

5.7%

1.3%

5.4%

$27.87

$-65.36

$-21.82

$-121.79

$142.33

$128.13

$58.93

$12.25

$4.12

$0.88

$3.87

Diluted EPS

$27.87

$27.85

$-65.36

$-21.82

$-121.79

$140.56

$128.13

$58.93

$12.25

$4.12

$0.88

$3.87

Weighted Avg Basic

—

27M

—

29M

30M

—

Weighted Avg Diluted

—

27M

—

29M

30M

—

BIO-RAD LABORATORIES, INC. (BIO) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does BIO-RAD LABORATORIES, INC. Do?

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. BIO-RAD LABORATORIES, INC. (BIO) is classified as a mid-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO Norman D. Schwartz and employs approximately 8,200 people, headquartered in Hercules, California. With a market capitalization of $7.5B, BIO is one of the notable companies in the Technology sector.

BIO-RAD LABORATORIES, INC. (BIO) Stock Rating — Hold (April 2026)

As of April 2026, BIO-RAD LABORATORIES, INC. receives a Hold rating with a composite score of 41.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.BIO ranks #1,811 out of 4,446 stocks in our coverage universe. Within the Technology sector, BIO-RAD LABORATORIES, INC. ranks #199 of 584 stocks, placing it in the upper half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BIO Stock Price and 52-Week Range

BIO-RAD LABORATORIES, INC. (BIO) currently trades at $279.25. The stock gained $1.75 (0.6%) in the most recent trading session. The 52-week high for BIO is $343.12, which means the stock is currently trading -18.6% from its annual peak. The 52-week low is $211.43, putting the stock 32.1% above its annual trough. Recent trading volume was 277K shares, suggesting relatively thin trading activity.

Is BIO Overvalued or Undervalued? — Valuation Analysis

BIO-RAD LABORATORIES, INC. (BIO) carries a value factor score of 47/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 10.83x, compared to the Technology sector average of 45.27x — a discount of 76%. The price-to-book ratio stands at 1.01x, versus the sector average of 3.16x. The price-to-sales ratio is 2.95x, compared to 1.06x for the average Technology stock. On an enterprise value basis, BIO trades at 46.11x EV/EBITDA, versus 12.79x for the sector.

Overall, BIO's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BIO-RAD LABORATORIES, INC. Profitability — ROE, Margins, and Quality Score

BIO-RAD LABORATORIES, INC. (BIO) earns a quality factor score of 44/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 9.3%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 6.6% versus the sector average of -1.0%.

On a margin basis, BIO-RAD LABORATORIES, INC. reports gross margins of 53.2%, compared to 50.9% for the sector. The operating margin is 8.9% (sector: -0.5%). Net profit margin stands at 27.0%, versus -1.5% for the average Technology stock. Revenue growth is running at 2.3% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BIO Debt, Balance Sheet, and Financial Health

BIO-RAD LABORATORIES, INC. has a debt-to-equity ratio of 16.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.62x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.20B. Cash and equivalents stand at $396M.

BIO has a beta of 0.98, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BIO-RAD LABORATORIES, INC. is 63/100, reflecting average volatility within the normal range for its sector.

BIO-RAD LABORATORIES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIO-RAD LABORATORIES, INC. reported revenue of $2.54B and earnings per share (EPS) of $27.87. Net income for the quarter was $693M. Gross margin was 53.2%. Operating income came in at $231M.

In FY 2025, BIO-RAD LABORATORIES, INC. reported revenue of $2.58B and earnings per share (EPS) of $27.87. Net income for the quarter was $760M. Gross margin was 51.9%. Revenue grew 0.7% year-over-year compared to FY 2024. Operating income came in at $47M.

In Q3 2025, BIO-RAD LABORATORIES, INC. reported revenue of $653M and earnings per share (EPS) of $-12.70. Net income for the quarter was $-342M. Gross margin was 52.6%. Revenue grew 0.5% year-over-year compared to Q3 2024. Operating income came in at $65M.

In Q2 2025, BIO-RAD LABORATORIES, INC. reported revenue of $652M and earnings per share (EPS) of $11.67. Net income for the quarter was $318M. Gross margin was 53.0%. Revenue grew 2.1% year-over-year compared to Q2 2024. Operating income came in at $77M.

Over the past 8 quarters, BIO-RAD LABORATORIES, INC. has demonstrated a growth trajectory, with revenue expanding from $638M to $2.54B. Investors analyzing BIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BIO Dividend Yield and Income Analysis

BIO-RAD LABORATORIES, INC. (BIO) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

BIO Momentum and Technical Analysis Profile

BIO-RAD LABORATORIES, INC. (BIO) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 17/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BIO vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, BIO-RAD LABORATORIES, INC. (BIO) ranks #199 out of 584 stocks based on the Blank Capital composite score. This places BIO in the upper half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing BIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BIO vs S&P 500 (SPY) comparison to assess how BIO-RAD LABORATORIES, INC. stacks up against the broader market across all factor dimensions.

BIO Next Earnings Date

No upcoming earnings date has been announced for BIO-RAD LABORATORIES, INC. (BIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BIO? — Investment Thesis Summary

BIO-RAD LABORATORIES, INC. presents a balanced picture with arguments on both sides. Low volatility (stability score 63/100) reduces downside risk.

In summary, BIO-RAD LABORATORIES, INC. (BIO) earns a Hold rating with a composite score of 41.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BIO stock.

Related Resources for BIO Investors

Explore more research and tools: BIO vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BIO head-to-head with peers: BIO vs IHS, BIO vs VRSN, BIO vs ESE.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology

The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral

Is It Time To Consider Buying Biome Australia Limited (ASX:BIO)?

A Look At Bio-Rad (BIO) Valuation After The Citi Downgrade And Price Target Cut

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Technology Stocks

BIO-RAD LABORATORIES, INC. (BIO) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does BIO-RAD LABORATORIES, INC. Do?

BIO-RAD LABORATORIES, INC. (BIO) Stock Rating — Hold (April 2026)

BIO Stock Price and 52-Week Range

Is BIO Overvalued or Undervalued? — Valuation Analysis

BIO-RAD LABORATORIES, INC. Profitability — ROE, Margins, and Quality Score

BIO Debt, Balance Sheet, and Financial Health

BIO-RAD LABORATORIES, INC. Revenue and Earnings History — Quarterly Trend

BIO Dividend Yield and Income Analysis

BIO Momentum and Technical Analysis Profile

BIO vs Competitors — Technology Sector Ranking and Peer Comparison

BIO Next Earnings Date

Should You Buy BIO? — Investment Thesis Summary

Related Resources for BIO Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology

The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral

Is It Time To Consider Buying Biome Australia Limited (ASX:BIO)?

A Look At Bio-Rad (BIO) Valuation After The Citi Downgrade And Price Target Cut